Background. There is a pressing need for development of oral antibiotics with activity against SBL-EB, particularly carbapenemase-producers, for use in the community or as step-down therapy for complicated urinary tract infection. VNRX-7145 is a novel boronic acid-based SBL inhibitor with no intrinsic activity that was designed as an orally bioavailable prodrug. The active moiety (VNRX-5236) is known to restore in vitro susceptibility to (CTB), an oral cephalosporin, among CTBresistant SBL-EB.
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Background.
Antiseptic wound ointments are increasing importance from safety, microbiological and public health points of view. Previously, Rosenblatt et al. (2017) has assessed polygalacturonic acid (PG) + caprylic acid (CAP) solution for biofilm eradication efficacy and cytotoxicity. In this study, we assessed biofilm eradication and cytotoxicity of PG+CAP wound ointment compared with commercially available wound ointment comparators.
Methods. Assessment of antimicrobial efficacy was conducted using a well-established biofilm model. Twenty-four-hour biofilm was formed on silicone discs and exposed wound ointments for 2 hours. Discs were then sonicated and cultured to quantitate any remaining viable biofilm. To assess cytotoxic effects of wound ointments, L-929 fibroblasts were exposed to 2% extracts of each ointment. The trypan exclusion test was used to access cell viability and Alamar blue was used to assess metabolic function. Ointments tested include, PG+CAP formulated in an inert ointment base, benzalkonium chloride quaternary ammonia antiseptic ointment (BZK), polyhexamethylene biguanide (PHMB) antiseptic ointment, and 2-hydroxyethylcellulose + glycerol inert ointment base. Untreated fibroblast cells were used as controls.
Results. Within 2 hours of exposure, PG+CAP ointment able to completely eradicate C. albicans (CA), MDR Pseudomonas aeruginosa (PS), and MRSA. Additionally, PG+CAP was significantly more efficacious than BZK for MRSA (P = 0.002) and PS (P = 0.015) and PHMB for MRSA (P = 0.02).
In the trypan blue exclusion test PG+CAP yielded 96.29% viable cells compared with 77.83% and 83.25%, for the QUAT and PHMB ointments, respectively. Fibroblasts treated with 2% PG+CAP, retained 86.6% of metabolic activity compared with untreated cells while the QUAT and PHMB ointments retained 37.5% and 44.5% metabolic activity, respectively.
Conclusion. PG+CAP has enhanced effects on eradication of biofilm in vitro as well as less toxicity in vitro relative to the antiseptic wound ointments. Further in vivo studies are warranted.
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Cardiac Safety in Adults with
Methods. In LEAP 1, PORT III-V patients received LEF 150mg IV q12h for 5-7 days or MOX 400mg IV q24h for 7 days, with optional IV-to-oral switch (600mg LEF q12h or 400 mg MOX q24h). In LEAP 2, PORT II-IV patients received oral LEF 600mg q12h for 5 days or oral MOX 400mg q24h for 7 days. Patients with known QT prolongation or on medication with potential to prolong the QT interval were excluded as per MOX label. After 5 minutes of rest in the supine position, triplicate 12-lead ECGs were obtained within a 5-minute interval at Screening in both studies, on Days 1/3 in LEAP 1 (predose and ≤15 minutes after first IV dose), and on Days 1/4 in LEAP 2 (predose and 1-3 hours after first oral dose), and sent to a central ECG reader for adjudication.
Results. Of 1,282 randomized/treated patients (n = 641/group), 1,274 had baseline (BL) and post-BL ECG data (n = 636 LEF, n = 638 MOX). Consistent with the resolution of infection, ECGs revealed mean reductions of 7-8 beats/minute for both groups in both studies. The largest mean change in QTcF from BL to post-BL was on Day 3 in LEAP 1 (13.6 and 16.4 msec with IV LEF and MOX, respectively) and on Day 4 in LEAP 2 (9.3 and 11.6 msec with oral LEF and MOX, respectively). The proportion of patients meeting potentially important post-BL QTcF values/changes was comparable between treatment groups (table). In the standardized MedDRA query of Torsade de pointes/QT prolongation (broad), the most common treatment-emergent adverse event was ECG QT prolonged (n = 4 LEF, n = 5 MOX). All events were nonserious and mild or moderate in severity. 6 events were considered study drug related (n = 4 LEF, n = 2 MOX). 5 events led to study drug discontinuation (n = 2 LEF, n = 3 MOX). In 2 patients with cardiovascular disease, 1 had ventricular arrhythmia on Day 20 (18 days after last LEF dose) and 1 had cardiac arrest on Day 18 (9 days after last MOX dose); both events were fatal and considered unrelated to study drug by investigator.
Conclusion. Mild prolongation of the QTcF interval was seen with LEF and MOX, with somewhat smaller effects seen with LEF. Given the small effect, LEF is unlikely to pose a clinically significant risk of ventricular proarrhythmia with appropriate precautions and use.
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An In Vitro Investigation of WCK 5222 (Cefepime/Zidebactam) and Currently Available Combination Antibiotic Regimens Against Enterobacteriaceae That Co-express Serine-β-Lactamase (SBL) and Metallo-β-Lactamase (MBL) Enzymes

Background.
Carbapenem-resistant Enterobacteriaceae (CRE) that simultaneously harbor SBLs and MBLs may demonstrate pan-drug resistance. Current
